{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:12:14Z","timestamp":1789049534303,"version":"build-2803163510"},"reference-count":42,"publisher":"American Chemical Society (ACS)","issue":"17","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Drugs targeting Bruton\u2019s tyrosine kinase (BTK) are recognized as key tools in hematological oncology. The clinical efficacy of BTK inhibitors is limited, however, by the emerging resistance driven by BTK mutations and the severe toxicity attributed to off-target kinase inhibition. PROteolysis TArgeting Chimeras (PROTACs) offer an alternative modality to address these major drawbacks. Herein, we present novel BTK-targeting PROTACs with a high potency against both the wild-type and the mutated BTK. Novel CRBN-binding warheads have been developed to mitigate the off-target protein degradation associated with anchors derived from thalidomide analogues. The linker optimization effort resulted in a series of potent, orally bioavailable BTK-targeting PROTACs without concomitant activity against IKZF1, IKZF3, and GSPT1. The lead compounds ISM-PR25 and ISM-PR44 demonstrate sufficient efficacy in degrading BTK protein in malignant B cells (DC50 = 0.04 and 0.05 nM, respectively) associated with a favorable DMPK profile and a large safety window regarding cell toxicity and effectively degraded BTK in mouse circulating B cells by single-dose oral treatment (3 mg\/kg).<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c01136","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:02:36Z","timestamp":1786723356000},"page":"20494-20519","source":"Crossref","is-referenced-by-count":0,"title":["Discovery of\nHighly Potent and Selective, Orally Bioavailable\nBTK-Targeting PROTACs Featuring Novel CRBN-Binding Warheads"],"prefix":"10.1021","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6533-7099","authenticated-orcid":true,"given":"Alexey B.","family":"Mantsyzov","sequence":"first","affiliation":[{"name":"Insilico Medicine AI Ltd. , ,","place":["Abu Dhabi, United Arab Emirates, 145748"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Insilico Medicine Shanghai Ltd. , ,","place":["Shanghai, China, 200120"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris G.","family":"Kruse","sequence":"additional","affiliation":[{"name":"Insilico Medicine AI Ltd. , ,","place":["Abu Dhabi, United Arab Emirates, 145748"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rostislav","family":"Petrov","sequence":"additional","affiliation":[{"name":"Insilico Medicine AI Ltd. , ,","place":["Abu Dhabi, United Arab Emirates, 145748"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fubao","family":"Huang","sequence":"additional","affiliation":[{"name":"Insilico Medicine Shanghai Ltd. , ,","place":["Shanghai, China, 200120"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Yu","sequence":"additional","affiliation":[{"name":"Insilico Medicine Shanghai Ltd. , ,","place":["Shanghai, China, 200120"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Cai","sequence":"additional","affiliation":[{"name":"Insilico Medicine Shanghai Ltd. , ,","place":["Shanghai, China, 200120"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3482-1870","authenticated-orcid":true,"given":"Xiao","family":"Ding","sequence":"additional","affiliation":[{"name":"Insilico Medicine AI Ltd. , ,","place":["Abu Dhabi, United Arab Emirates, 145748"]},{"name":"Insilico Medicine Shanghai Ltd. , ,","place":["Shanghai, China, 200120"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3976-3991","authenticated-orcid":true,"given":"Vladimir","family":"Aladinskiy","sequence":"additional","affiliation":[{"name":"Insilico Medicine AI Ltd. , ,","place":["Abu Dhabi, United Arab Emirates, 145748"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Aliper","sequence":"additional","affiliation":[{"name":"Insilico Medicine AI Ltd. , ,","place":["Abu Dhabi, United Arab Emirates, 145748"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9157-9182","authenticated-orcid":true,"given":"Feng","family":"Ren","sequence":"additional","affiliation":[{"name":"Insilico Medicine Shanghai Ltd. , ,","place":["Shanghai, China, 200120"]},{"name":"Insilico Medicine Hong Kong Ltd. , Pak Shek Kok , ,","place":["New Territories, Hong Kong, 999077"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Zhavoronkov","sequence":"additional","affiliation":[{"name":"Insilico Medicine AI Ltd. , ,","place":["Abu Dhabi, United Arab Emirates, 145748"]},{"name":"Insilico Medicine Shanghai Ltd. , ,","place":["Shanghai, China, 200120"]},{"name":"Insilico Medicine Hong Kong Ltd. , Pak Shek Kok , ,","place":["New Territories, Hong Kong, 999077"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"2026091009072853600_cit1","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1542\/peds.9.6.722","article-title":"First Report\nDescribing Humoral Immunodeficiency in a Male Child with a Disease\nLater Termed X-Linked Agammablobulinemia (XLA) and Attributed to Bruton\u2019s\nTyrosine Kinase Difficiency","volume":"9","author":"Bruton","year":"1952","journal-title":"Pediatrics"},{"issue":"6409","key":"2026091009072853600_cit2","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/361226a0","article-title":"The Gene Involved in X-Linked Agammaglobulinaemia\nIs\na Member of the Src Family of Protein-Tyrosine Kinases","volume":"361","author":"Vetrie","year":"1993","journal-title":"Nature"},{"issue":"25","key":"2026091009072853600_cit3","doi-asserted-by":"publisher","first-page":"15595","DOI":"10.1074\/jbc.272.25.15595","article-title":"Transphosphorylation\nof Bruton\u2019s Tyrosine Kinase\non Tyrosine 551 Is Critical for B Cell Antigen Receptor Function","volume":"272","author":"Kurosaki","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"5250","key":"2026091009072853600_cit4","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1126\/science.271.5250.822","article-title":"Activation\nof BTK by a Phosphorylation Mechanism Initiated by SRC Family Kinases","volume":"271","author":"Rawlings","year":"1996","journal-title":"Science"},{"issue":"42","key":"2026091009072853600_cit5","doi-asserted-by":"publisher","first-page":"38595","DOI":"10.1074\/jbc.M103675200","article-title":"Four Tyrosine\nResidues in Phospholipase C-\u03932, Identified as Btk-Dependent\nPhosphorylation Sites, Are Required for B Cell Antigen Receptor-Coupled\nCalcium Signaling","volume":"276","author":"Watanabe","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"3","key":"2026091009072853600_cit6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B Cell Receptor Signalling in Cancer: Preclinical\nand Clinical Advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"23","key":"2026091009072853600_cit7","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton Tyrosine Kinase Represents a Promising Therapeutic\nTarget for Treatment of Chronic Lymphocytic Leukemia and Is Effectively\nTargeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2026091009072853600_cit8","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41571-024-00956-1","article-title":"Navigating the Changing Landscape\nof BTK-Targeted Therapies\nfor B Cell Lymphomas and Chronic Lymphocytic Leukaemia","volume":"21","author":"Stanchina","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"2026091009072853600_cit9","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1002\/eji.1830231210","article-title":"The Bruton\u2019s Tyrosine Kinase Gene Is Expressed\nthroughout B Cell Differentiation, from Early Precursor B Cell Stages\nPreceding Immunoglobulin Gene Rearrangement up to Mature B Cell Stages","volume":"23","author":"De Weers","year":"1993","journal-title":"Eur. J. Immunol."},{"issue":"8","key":"2026091009072853600_cit10","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B Cell Receptor Signaling with Ibrutinib\nin Diffuse Large B Cell Lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat. Med."},{"issue":"2","key":"2026091009072853600_cit11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40265-014-0178-8","article-title":"Ibrutinib: First Global\nApproval","volume":"74","author":"Cameron","year":"2014","journal-title":"Drugs"},{"issue":"6682","key":"2026091009072853600_cit12","doi-asserted-by":"publisher","DOI":"10.1126\/science.adi5798","article-title":"Kinase-Impaired BTK Mutations Are Susceptible to Clinical-Stage\nBTK and IKZF1\/3 Degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"issue":"4","key":"2026091009072853600_cit13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein Degraders Enter the Clinic\n\u2500 a New Approach to Cancer Therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat.\nRev. Clin. Oncol."},{"issue":"26","key":"2026091009072853600_cit14","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","article-title":"Targeting the C481S Ibrutinib-Resistance\nMutation in Bruton\u2019s Tyrosine Kinase Using PROTAC-Mediated\nDegradation","volume":"57","author":"Buhimschi","year":"2018","journal-title":"Biochemistry"},{"issue":"Supplement 1","key":"2026091009072853600_cit15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1182\/blood-2025-86","article-title":"Bexobrutideg (NX-5948), a Novel Bruton\u2019s\nTyrosine Kinase (BTK) Degrader, Demonstrates Rapid and Durable Clinical\nResponses in Relapsed\/Refractory Chronic Lymphocytic Leukemia (CLL):\nNew and Updated Findings from an Ongoing Phase 1a\/b Trial","volume":"146","author":"Omer","year":"2025","journal-title":"Blood"},{"issue":"13","key":"2026091009072853600_cit16","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1182\/blood.2022016934","article-title":"NRX-0492 Degrades Wild-Type and C481 Mutant BTK and\nDemonstrates in Vivo Activity in CLL Patient-Derived Xenografts","volume":"141","author":"Zhang","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2026091009072853600_cit17","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1021\/acs.jmedchem.3c01007","article-title":"Discovery\nand Preclinical\nPharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton\u2019s\nTyrosine Kinase with Immunomodulatory Activity for the Treatment of\nPatients with B Cell Malignancies","volume":"67","author":"Robbins","year":"2024","journal-title":"J. Med. Chem."},{"issue":"15","key":"2026091009072853600_cit18","doi-asserted-by":"publisher","first-page":"15960","DOI":"10.1021\/acs.jmedchem.5c00956","article-title":"Discovery of TQ-3959\nas a Potent and Orally Bioavailable BTK PROTAC Degrader Incorporating\na Novel Benzisoxazole-Based CRBN Ligand for the Treatment of B-Cell\nMalignancies","volume":"68","author":"Ren","year":"2025","journal-title":"J. Med. Chem."},{"issue":"11","key":"2026091009072853600_cit19","doi-asserted-by":"publisher","first-page":"7454","DOI":"10.1021\/acs.jmedchem.3c00176","article-title":"Discovery of Novel\nBruton\u2019s\nTyrosine Kinase PROTACs with Enhanced Selectivity and Cellular Efficacy","volume":"66","author":"Li","year":"2023","journal-title":"J. Med. Chem."},{"key":"2026091009072853600_cit20","doi-asserted-by":"publisher","first-page":"117420","DOI":"10.1016\/j.ejmech.2025.117420","article-title":"Synthesis, and Biological\nEvaluation of Novel BTK-Targeting Proteolysis Targeting Chimeras (PROTACs)\nwith Enhanced Pharmacokinetic Properties","volume":"289","author":"Lin","year":"2025","journal-title":"Eur.\nJ. Med. Chem."},{"issue":"S3","key":"2026091009072853600_cit21","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000971772.24358.c2","article-title":"BGB-16673, a BTK Degrader, Overcomes on-Target Resistance from BTK\nInhibitors and Represents Sustainable Long-Term Tumor Regression in\nLymphoma Xenograft Models","volume":"7","author":"Wang","year":"2023","journal-title":"HemaSphere"},{"issue":"Supplement 1","key":"2026091009072853600_cit22","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1182\/blood-2023-179872","article-title":"A First-in-Human Phase\n1 Trial of NX-2127, a First-in-Class Bruton\u2019s Tyrosine Kinase\n(BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity,\nin Patients with Relapsed\/Refractory B Cell Malignancies","volume":"142","author":"Danilov","year":"2023","journal-title":"Blood"},{"issue":"Supplement\n1","key":"2026091009072853600_cit23","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1182\/blood-2025-3583","article-title":"Updated Efficacy\nand Safety Results of the Bruton Tyrosine Kinase Degrader BGB-16673\nin Patients with Relapsed\/Refractory Waldenstro\u0308m Macroglobulinemia\nfrom the Ongoing Phase 1 CaDAnCe-101 Study","volume":"146","author":"Tam","year":"2025","journal-title":"Blood"},{"issue":"21","key":"2026091009072853600_cit24","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70132","article-title":"Proteolysis-targeting\nChimeras in Cancer Therapy: Targeted Protein Degradation for Next-generation\nTreatment","volume":"131","author":"Anaya","year":"2025","journal-title":"Cancer"},{"issue":"3","key":"2026091009072853600_cit25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC\nTargeted Protein Degraders:\nThe Past Is Prologue","volume":"21","author":"Be\u0301ke\u0301s","year":"2022","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"3","key":"2026091009072853600_cit26","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3390\/cancers17030557","article-title":"BTK Is the Target That Keeps on Giving:\nA Review of BTK-Degrader Drug Development, Clinical Data, and Future\nDirections in CLL","volume":"17","author":"Salvaris","year":"2025","journal-title":"Cancers"},{"issue":"5971","key":"2026091009072853600_cit27","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a\nPrimary Target of Thalidomide Teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"6414","key":"2026091009072853600_cit28","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat0572","article-title":"Defining\nthe Human C2H2 Zinc Finger Degrome Targeted by Thalidomide Analogs\nthrough CRBN","volume":"362","author":"Sievers","year":"2018","journal-title":"Science"},{"issue":"Supplement 1","key":"2026091009072853600_cit29","doi-asserted-by":"publisher","first-page":"7108","DOI":"10.1182\/blood-2022-157939","article-title":"Mezigdomide (CC-92480), a Novel Cereblon\nE3 Ligase Modulator, Induces Vulnerability of Multiple Myeloma Cells\nto T-Cell-Mediated Killing","volume":"140","author":"Gaffney","year":"2022","journal-title":"Blood"},{"issue":"7611","key":"2026091009072853600_cit30","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A Novel Cereblon Modulator Recruits\nGSPT1 to the CRL4CRBN Ubiquitin Ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"issue":"5","key":"2026091009072853600_cit31","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1182\/blood.2020008676","article-title":"CC-90009,\na Novel Cereblon E3 Ligase Modulator, Targets Acute Myeloid Leukemia\nBlasts and Leukemia Stem Cells","volume":"137","author":"Surka","year":"2021","journal-title":"Blood"},{"issue":"6241","key":"2026091009072853600_cit32","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Phthalimide Conjugation as a Strategy\nfor in Vivo Target Protein Degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"issue":"1","key":"2026091009072853600_cit33","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1182\/bloodadvances.2022008121","article-title":"Orally Bioavailable\nBTK PROTAC Active against Wild-Type and C481 Mutant BTKs in Human\nLymphoma CDX Mouse Models","volume":"7","author":"Lim","year":"2023","journal-title":"Blood Adv."},{"issue":"Supplement 1","key":"2026091009072853600_cit34","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1182\/blood-2021-147473","article-title":"Nx-5948, a\nSelective Degrader of BTK with Activity in Preclinical Models of Hematologic\nand Brain Malignancies","volume":"138","author":"Robbins","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"2026091009072853600_cit35","doi-asserted-by":"publisher","first-page":"5833","DOI":"10.1182\/blood-2024-202909","article-title":"Bgb-16673, a Selective\nBTK Degrader, Exhibits Deeper\nInhibition of Cancer Cell Signaling Pathways and Better Efficacy in\nMCL Models","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2026091009072853600_cit36","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1021\/acsmedchemlett.5c00080","article-title":"Identification of Novel\nPan-KRAS Inhibitors via Structure-Based Drug Design, Scaffold Hopping,\nand Biological Evaluation","volume":"16","author":"Aladinskiy","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"issue":"6","key":"2026091009072853600_cit37","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1039\/D2SC05709C","article-title":"AlphaFold Accelerates Artificial\nIntelligence Powered Drug Discovery: Efficient Discovery of a Novel\nCDK20 Small Molecule Inhibitor","volume":"14","author":"Ren","year":"2023","journal-title":"Chem. Sci."},{"issue":"3","key":"2026091009072853600_cit38","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1021\/acs.jcim.2c01191","article-title":"Chemistry42:\nAn AI-Driven Platform for Molecular Design\nand Optimization","volume":"63","author":"Ivanenkov","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"2026091009072853600_cit39","unstructured":"Mantsyzov, A.; Kruse, C.; Aladinskiy, V.; Ren, F.\n          CRBN-Binding Compounds and Uses Thereof. WO 2,026,026,826 A1, 2026."},{"key":"2026091009072853600_cit40","unstructured":"Zhaozhong, J.; William, J.; Thomas, D.; Wei, C.\n          Heterocyclecarboxamides as Inhibitors\nof Bruton\u2019s Tyrosine Kinase and Their Preparation. WO 2,015,084,998\nA1, 2015."},{"issue":"7","key":"2026091009072853600_cit41","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41589-018-0055-y","article-title":"Plasticity in Binding Confers Selectivity in Ligand-Induced\nProtein Degradation","volume":"14","author":"Nowak","year":"2018","journal-title":"Nat. Chem. Biol."},{"issue":"7","key":"2026091009072853600_cit42","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/(SICI)1096-987X(199905)20:7&lt;720::AID-JCC7&gt;3.0.CO;2-X","article-title":"MMFF94s Option for Energy Minimization Studies","volume":"20","author":"Halgren","year":"1999","journal-title":"J. Comput. Chem."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c01136","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/17\/20494\/66549666\/acs.jmedchem.6c01136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/17\/20494\/66549666\/acs.jmedchem.6c01136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:30:28Z","timestamp":1789047028000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/17\/20494\/5255716\/Discovery-of-Highly-Potent-and-Selective-Orally"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":42,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,8,14]]},"published-print":{"date-parts":[[2026,9,10]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c01136","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]}}}